Repros Therapeutics 3Q Loss Widens
13th Nov 2006, 20:17 GMT
Repros Therapeutics a drug maker specializing in treatments for reproductive conditions, said its Q3 loss widened, due mostly to greater spending on R&D.
Repros Therapeutics 3Q Loss Widens related news:
- Chelsea Therapeutics posts 3Q loss — Latest news from Charlotte Business Journal
- Iomai 3Q Loss Widens — StratWire - Business of Healthcare NewsFeed
- Novavax 3Q Loss Widens on Research Costs — Operations-Related News from StratCenter.com
- Favrille 3Q Loss Widens on Costs — StratWire - Business of Healthcare NewsFeed
- GMH 3Q loss widens, no guidance offered — bizjournals.com Banking & Financial Services:Investing headlines
- CHAD Therapeutics revenue down, loss up in 2Q — Latest news from Los Angeles Business from bizjournals
- PFSweb loss widens — bizjournals.com High Tech:E-Commerce headlines
- US LEC loss widens in third quarter — Latest news from Charlotte Business Journal
- Revenues decline, loss widens for Spheris Inc. — Latest news from Nashville Business Journal
- PokerTek posts 3Q loss of $2.3M — Latest news from Charlotte Business Journal
Latest news from Financial News News from StratCenter.com:
- TRADE NEWS: Agilent Technologies Introduces High-Speed, High-Volume USB Multifunction Data Acquisition Modules, Chassis
- Bio-Rad Closes Buy of Ciphergen Unit
- The LGL Group Reports Q3 Earnings
- Analogic CEO to retire
- Analogic CEO Plans to Retire
- Meade Instruments Contracts with Leading Asian Outsource Manufacturing Firm
- JMAR Receives Nasdaq Delisting Notice
- Analogic Corp Announces Mgmt Changes
- Bio-Rad Purchases Life Science Research Business From Ciphergen Biosystems
- Agilent to buy Switzerland's Acqiris